Drug Action Exam 3 Flashcards
radial muscle adrenergic receptor and effect
alpha-1, contraction causing dilation of pupil
radial muscle cholinergic receptor and action
None
mydriasis
dilation of pupil
miosis
shrinking of pupil
iris sphincter cholinergic receptor and effect
M3; contraction causing miosis
iris sphincter adrenergic receptor and effect
none
ciliary epithelium cholinergic receptor and effect
none
ciliary epithelium adrenergic receptor and effect
beta-2 increase aqueous producting increase IOP < alpha-2 decreases aqueous production decrease IOP
trabecular meshwork cholinergic receptor and effect
none
trabecular meshwork adrenergic receptor and effect
beta-2 increase aqueous outflow decrease IOP
atria and ventricles cholinergic receptor and effect
M2>M3, decrease contractility and force
atria and ventricles adrenergic receptor and effect
beta-1>beta-2; increase contractility and force
SA and AV nodes cholinergic receptor and effect
M2>M3; decrease heart rate
SA and AV nodes adrenergic receptor and effect
beta-1>beta-2; increase heart rate
arteries and veins cholinergic receptor and effect
M3; vasodilation, decreased BP
arteries and veins adrenergic receptor and effect
alpha-1, vasoconstriction increased BP
alpha-2, beta-2, vasodilation decreased BP
skeletal muscle blood vessels cholinergic receptor and effect
none
skeletal muscle blood vessels adrenergic receptors and effect
beta-2, vasodilation
bronchial smooth muscle cholinergic receptor and effect
M3, bronchoconstriction
bronchial smooth muscle adrenergic receptor and effect
beta-2, bronchodilation
stomach motility and tone cholinergic receptor and effect
M2, M3; increased motility and tone
stomach motility and tone adrenergic receptor and effect
alpha-1, alpha-2, beta-1, beta-2; decreased motility and tone
GI sphincters cholinergic receptor and effect
M2,M3; relaxation
GI sphincters adrenergic receptor and effect
alpha-1; contraction
GI secretions cholinergic receptor and effect
M2, M3; increase secretions
GI secretions adrenergic receptor and effect
alpha-2; decrease secretion
renin release cholinergic receptor and effect
none
renin release adrenergic receptor and effect
beta-1, increase renin release
pancreas beta cells cholinergic receptor and effect
none
pancreas beta cells adrenergic receptor and effect
alpha-2 decrease insulin secretion > beta-2 increase insulin secretion
sweat glands cholinergic receptor and effect
none
sweat glands adrenergic receptor and effect
alpha-1 (localized), M2, M3; increase sweat
urinary bladder detrussor cholinergic receptor and effect
M3>M2; contraction
urinary bladder detrussor adrenergic receptor and effect
beta-2, beta-3 (dominant); relaxation
urinary bladder trigone and sphincter cholinergic receptor and effect
M3>M2; relaxation
urinary bladder trigone adrenergic receptor and effect
alpha-1, contraction
Epi is agonist at
alpha-1, alpha-2, beta-1, beta-2, beta-3
Norepi is agonist at
alpha-1, beta-1 > beta-2
glaucoma IOP
> 26 mmHg
pilocarpine eye
muscarinic agonist; open angle glaucoma, reverse mydriasis
benthanecol GI
increase GI motility postsurgery
pilocarpine GI
muscarinic agonist; xerostomia, Sjorgen’s syndrome; increase salivation/secretions
bethanochol GU
stimulates detrussor muscle to contract; for postop urinary retention
pyridostigmine
myasthenia gravis, treat nondepolarizing neuromuscular blockers; reversible AChEI
neostigmine
myasthenia gravis, reverse nondepolarizing neuromuscular blocking agents, treatment of postop urinary retential and intestinal atony; reversible AChEI
physostigmine
glaucoma, myasthenia gravis, treatment of overdose of agents with significant anticholinergic activity; reversible AChEI
donepezil
AD; reversible nonclassical AChEI
galantamine
AD; reversible nonclassical AChEI
rivastigmine
AD; reversible classical AChEI and BuChEI
tacrine
AD; reversible nonclassical AChEI
malathion
lice; irreversible AChEI
Echothiophate
glaucoma; irreversible AChEI
diazinon
insecticides; irreversible AChEI
sarin, soman
nerve gas; irreversible AChEI
pralidoxime
organophosphate antidote
atropine cardiac
muscarinic antagonist; increase HR to treat AV nodal hert block, sinus bradycardia
ipatropium Br
COPD, prevent asthma, rhinorrhea; muscarinic antagonist M1 M3
tiotropium
COPD; muscarinic antagonist
aclidinium Br
COPD; muscarinic antagonist
scopalamine
motion sickness; muscarinic antagonist
Lomitil
muscarinic antagonist; IBS w/diarrhea
dicyclomine
muscarinic antagonist; IBS/diarrhea
tropicamide
muscarinic antagonist, cyclopegic mydriatic; ocular diagnostic agent
ditropan IR
nonselective muscarinic antagonist; urinary incontinence
ditropan IR SE
D: 71%
C: 15%
Ditropan XL
muscarinic antagonist; urinary incontinence
Ditropan XL SE
D: 45%
C: 10%
Oxytrol
muscarinic antagonist; urinary incontinence
Oxytrol SE
D: 7%
C: 3%
Gelnique
muscarinic antagonist; urinary incontinence
Gelnique SE
D: 7%
C: 1%
Detrol
nonselective muscarinic antagonist; urinary incontinence
Detrol SE
D: 35%
C: 7%
Detrol LA
nonselective muscarinic antagonist; urinary incontinence
Detrol LA SE
D: 25%
C: 6%
Sanctura
nonselective muscarinic antagonist; urinary incontinence
Sancture SE
D: 6:
C: 5%
Sanctura SR
nonselective muscarinic antagonist; urinary incontinence
Sanctura SR SE
D: 11%
C: 9%
Enablex
muscarinic antagonist; urinary incontinence
Enablex SE
D: 20%
C: 15%
Toviaz
muscarinic antagonist; urinary incontinence
VESIcare
muscarinic antagonist; urinary incontinence
VESIcare SE
D: 20%
C: 9%
G protein beta-gamma subunit
increase K channels, decrease Ca channels, increase PI3 K
M2, M4
Gi decrease cAMP
M1, M3, M5
Gq activate PLC produce DAG IP3
ACh eye
cholinergic agonist; ocular surgery
carbachol
cholinergic agonist; glaucoma, miosis during surgery
methacholine
muscarinic agonist; diagnostic agent for asthma/COPD
cevimeline HCl
muscarininc agonist; dry mouth d/t Sjorgen’s syndrome
varenicline tartrate
alpha-4-beta-2 nicotinic partial agonist; smoking cessation
Edrophonium Cl
nonclassical reversible AChEI; diagnosis of myasthenia gravis, reverse nondepolarizing neuromuscular blocking agents
demecarium Br
glaucoma; reversible AChEI
abenonium Cl
myasthenia gravis; reversible AChEI
carbaryl
insecticide; reversible AChEI
isoflurophate
glaucoma; irreversible AChEI
VX
nerve gas; irreversible AChEI
Parathion
insecticide; irreversible AChEI
memantine
AD; NMDA antagonist
atropine
muscarinic antagonist; GI antispasmodic, antidote for poisoning/overdose of muscarinic agents, cholinesterasse inhibitors, organophosphates, ophthalmic
hyoscyamine
muscarinic antagonist; GI disorders, hypermotility of urinary tract, PUB, IBS, enterocolitis, diverticulitis, abdominal cramps, biliary and renal colic
belladonna tincture
muscarinic antagonist; antidysmenorrheal, antivertigo, nocturnal enuresis, antisialogogue
glycopyrrolate
muscarinic antagonist; PUD, decrease gastric acid secretion, prophylaxis of hypersecretory conditions
clinidium Br
muscarinic antagonist; GI antispasmodic, decrease acid secretion
propantheline br
muscarinic antagonist; GI antispasmodic, PUD
Mepenzolate Br
muscarinic antagonist; GI antispasmodic
benzotropine mesylate
muscarinic antagonist; parkinsonism
trihexyphenidyl HCl
muscarinic antagonist; parkinsonism
diphenhydramine
muscarinic antagonist, antihistamine; parkinsonism, antiemetic/antivertigo
cyclizine HCl
antihistamine; antiemetic/antivertigo
meclizine HCl
antihistamine; antiemetic/antivertigo
cyclopentolate HCl
muscarinic antagonist, cyclopegic mydriatic; ocular diagnostic agent
homotropine Br
muscarinic antagonist, cyclopegic mydriatic
atracurium Br
nondepolarizing neuromuscular blocking agent
cistracurium besylate
nondepolarizing neuromuscular blocking agent
pancuronium Br
nondepolarizing neuromuscular blocking agent
vercuronium Br
nondepolarizing neuromuscular blocking agent
rocuronium Br
nondepolarizing neuromuscular blocking agent
decamethonium
depolarizing neuromuscular blocking agent
succinylcholine Cl
depolarizing neuromuscular blocking agent
sugammadex
immediately and rapidly decreases NMBA concentrations